Beta Bionics (NASDAQ:BBNX) Now Covered by Analysts at Robert W. Baird

Investment analysts at Robert W. Baird began coverage on shares of Beta Bionics (NASDAQ:BBNX - Get Free Report) in a note issued to investors on Thursday, MarketBeat.com reports. The brokerage set a "neutral" rating and a $20.00 price target on the stock. Robert W. Baird's target price indicates a potential downside of 3.10% from the stock's current price.

Beta Bionics Stock Up 0.3 %

Shares of NASDAQ BBNX traded up $0.07 on Thursday, hitting $20.64. The company's stock had a trading volume of 259,379 shares, compared to its average volume of 337,780. Beta Bionics has a 12-month low of $20.00 and a 12-month high of $24.50.

Insider Activity at Beta Bionics

In other news, major shareholder Hadley Harbor Aggre Wellington bought 1,000,000 shares of the stock in a transaction on Friday, January 31st. The stock was purchased at an average cost of $17.00 per share, with a total value of $17,000,000.00. Following the purchase, the insider now owns 3,901,599 shares of the company's stock, valued at approximately $66,327,183. The trade was a 34.46 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, insider Mike Mensinger purchased 33,350 shares of Beta Bionics stock in a transaction on Friday, January 31st. The shares were acquired at an average cost of $17.00 per share, for a total transaction of $566,950.00. Following the purchase, the insider now owns 59,019 shares in the company, valued at approximately $1,003,323. This trade represents a 129.92 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

Remove Ads

Beta Bionics Company Profile

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.